npj Vaccines (Apr 2024)

Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine

  • Xiaohua Ye,
  • David J. H. Shih,
  • Zhiqiang Ku,
  • Junping Hong,
  • Diane F. Barrett,
  • Richard E. Rupp,
  • Ningyan Zhang,
  • Tong-Ming Fu,
  • W. Jim Zheng,
  • Zhiqiang An

DOI
https://doi.org/10.1038/s41541-024-00860-w
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Human cytomegalovirus (HCMV) is a leading infectious cause of birth defects and the most common opportunistic infection that causes life-threatening diseases post-transplantation; however, an effective vaccine remains elusive. V160 is a live-attenuated replication defective HCMV vaccine that showed a 42.4% efficacy against primary HCMV infection among seronegative women in a phase 2b clinical trial. Here, we integrated the multicolor flow cytometry, longitudinal T cell receptor (TCR) sequencing, and single-cell RNA/TCR sequencing approaches to characterize the magnitude, phenotype, and functional quality of human T cell responses to V160. We demonstrated that V160 de novo induces IE-1 and pp65 specific durable polyfunctional effector CD8 T cells that are comparable to those induced by natural HCMV infection. We identified a variety of V160-responsive T cell clones which exhibit distinctive “transient” and “durable” expansion kinetics, and revealed a transcriptional signature that marks durable CD8 T cells post-vaccination. Our study enhances the understanding of human T-cell immune responses to V160 vaccination.